stockrowLakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +198.9%
- Free cash flow
- +18.2%
Quarter to June 2026, against a year earlier
Follow LKFT
Alert me
Lakefront Biotherapeutics - Sponsored ADR (LKFT) EPS (diluted)
Lakefront Biotherapeutics - Sponsored ADR's EPS (diluted) for fiscal 2025 was $5.51, up 355.4% from $1.21 in fiscal 2024. Over the twelve months to 31 March 2026 it was −$0.29. Over the past ten years it has ranged from −$5.46 (fiscal 2020) to $5.51 (fiscal 2025) — the current reading is the highest in ten years. Lakefront Biotherapeutics - Sponsored ADR ranks 94th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $5.51 | 355.37% |
| FY2024 | $1.21 | (65.13%) |
| FY2023 | $3.47 | — |
| FY2022 | −$3.50 | — |
| FY2021 | −$1.87 | — |
| FY2020 | −$5.46 | — |
| FY2019 | $2.79 | — |
| FY2018 | −$0.66 | — |
| FY2017 | −$2.64 | — |
| FY2016 | $1.24 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Mar 2026 | $0.26 | — |
| Mar 2025 | −$2.45 | — |
| Mar 2024 | $1.49 | 259.12% |
| Sep 2023 | $0.41 | 376.90% |
| 28 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $2.29 |
| VCEL Vericel Corporation compare | $0.65 |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | −$0.29 |
| SEPN Septerna, Inc. compare | −$0.54 |
| ZYME Zymeworks Inc. compare | −$2.02 |
| IMNM Immunome, Inc. compare | −$2.53 |
| BHVN Biohaven Ltd. compare | −$3.86 |
| PVLA Palvella Therapeutics, Inc. compare | −$4.83 |
| VERA Vera Therapeutics, Inc. compare | −$5.86 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on LKFT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement